DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Tucatinib is an investigational drug.
There have been 10 clinical trials for Tucatinib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Meningeal Neoplasms, and Rectal Neoplasms. The leading clinical trial sponsors are Seattle Genetics, Inc., Cascadian Therapeutics Inc., and Translational Breast Cancer Research Consortium.
There are six US patents protecting this investigational drug and one hundred and one international patents.
Recent Clinical Trials for Tucatinib
|A Study of Tucatinib vs. Placebo in Combination With Trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer||Seattle Genetics, Inc.||Phase 3|
|A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects||Seattle Genetics, Inc.||Phase 1|
|Tucatinib + Abemaciclib + Herceptin for HER2+ MBC||Eli Lilly and Company||Phase 1|
Top disease conditions for Tucatinib
Top clinical trial sponsors for Tucatinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tucatinib||Start Trial||Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them||Array BioPharma Inc. (Boulder, CO)||Start Trial|
|Tucatinib||Start Trial||N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases||Array Biopharma, Inc. (Boulder, CO)||Start Trial|
|Tucatinib||Start Trial||Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them||Array BioPharma Inc. (Boulder, CO)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|